[Asia Economy Reporter Hwang Yoon-joo] Hanmi Pharm announced on the 25th that the U.S. expedited approval for the lung cancer new drug 'Poziotinib,' which it directly developed and licensed to Spectrum in the U.S., has been delayed.
Hanmi Pharm stated, "On December 6, 2021, Spectrum submitted a New Drug Application (NDA) for 'Poziotinib' to the U.S. Food and Drug Administration (FDA), and at this time, we have received a Complete Response Letter (CRL) indicating that Poziotinib cannot be approved."
▲ Gangwon Energy = Acquired a patent for a powder raw material drying device for secondary battery manufacturing equipped with an electric heater.
▲ Kyungchang Industry = Announced that it has fully recovered KRW 10 billion in monetary loans to affiliates following the complete sale of shares in KB Wiper System Co., Ltd., a joint venture between its affiliate KCW Co., Ltd. and BOSCH.
▲ KG Steel = Announced plans to dispose of hot-rolled electric furnace-related facilities worth KRW 90.6 billion to improve financial structure. This accounts for 3.27% of total assets.
▲ Korea Asset Trust = Announced that the 2022 cash dividend is expected to be around KRW 220 per common share, and no stock dividends will be issued.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
